TY - JOUR
T1 - Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma
T2 - Ocular Oncology Study Consortium report 4
AU - Ocular Oncology Study Consortium
AU - Seider, Michael I.
AU - Berry, Duncan E.
AU - Schefler, Amy C.
AU - Materin, Miguel
AU - Stinnett, Sandra
AU - Mruthyunjaya, Prithvi
AU - Raufi, Nikolas N.
AU - Harbour, J. William
AU - Berry, Jesse L.
AU - Kim, Jonathan
AU - Skalet, Alison
AU - Miller, Audra
AU - Liu, Tiffany
AU - Demirci, Hakan
AU - Ozkurt, Zeynep G.
AU - Hovland, Peter
AU - Aaberg, Thomas
AU - Kim, Ryan S.
AU - Tann, Anne
N1 - Funding Information:
Prithvi Mruthyunjaya serves as a consultant for Castle Biosciences, Optos Inc., Santen, EyePoint Pharmaceuticals, and Arix Biosciences. Miguel Materin serves as a consultant for Castle Biosciences. Amy Schefler serves as a consultant for Castle Biosciences (grant funding), Aura Biosciences (consultant, grant funding); Regeneron (grant funding) and Genentech (consultant, grant funding). Duncan Berry declares he has no conflict of interest. Michael I. Seider declares he has no conflict of interest. Sandra Stinnett declares she has no conflict of interest.
Funding Information:
This study was funded by The Heed Ophthalmic Fellowship - (M.Seider), The Childress Family Foundation (NC), unrestricted departmental funding from Research to Prevent Blindness (New York, NY) and by grant P30 EY010572 from the National Institutes of Health (Bethesda, MD) – (P.Mruthyunjaya).
Funding Information:
The following are Ocular Oncology Study Consortium members: Duke Eye Center, Durham, NC (coordinating center) : Prithvi Mruthyunjaya, MD, MHS (Study PI), Miguel Materin, MD, Michael I. Seider, MD, Duncan E. Berry, MD, Nikolas N. Raufi, MD, Sandra Stinnett, DrPH; University of Miami/Bascom Palmer Eye Institute, Miami, FL: J. William Harbour, MD; University of Southern California/USC Roski Eye Institute, Los Angeles, CA: Jesse L. Berry, MD, and Jonathan Kim, MD; Oregon Health Sciences/Casey Eye Institute, Portland, OR: Alison Skalet, MD, PhD, and Audra Miller, MD; Smilow Cancer Hospital at Yale New Haven, New Haven, CT: Miguel Materin, MD, and Tiffany Liu, MD; University of Michigan, Ann Arbor, MI: Hakan Demirci, MD, and Zeynep G. Ozkurt, MD; Colorado Retina Associates, Rocky Vista University, Denver, CO: Peter Hovland, MD, PhD; Retina Specialists of Michigan, Grand Rapids, MI and Michigan State University, East Lansing, MI: Thomas Aaberg, Jr., MD; Retina Consultants of Houston/Blanton Eye Institute at Houston Methodist Hospital, Houston TX: Amy C. Schefler, MD, Ryan S. Kim, and Anne Tann, MD (Department of Radiation Oncology, Houston Methodist Hospital).
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Purpose: To investigate the relationship between surgical approach for intraocular tumor biopsy of uveal melanoma and tumor morphologic features such as size and intraocular location and the effect of these variables on diagnostic yield and biopsy outcome. Methods: Consecutive patients from nine Ocular Oncology centers with uveal melanoma (UM) undergoing tumor biopsy immediately preceding I125 plaque brachytherapy with tissue sent for gene expression profiling (GEP) testing were reviewed retrospectively. Results: Three hundred sixty patients were included (50% men, mean age 60.2 years). Overall biopsy yield was 99% and 83% for GEP and cytopathology, respectively. Surgeon choice of biopsy approach (trans-vitreal vs. trans-scleral) was found to associate with both tumor location and tumor thickness. A trans-scleral rather than trans-vitreal approach was used more commonly for anteriorly located tumors (92% vs. 38% of posterior tumors, p < 0.001) and thicker tumors (86% vs. 55% of thin tumors, p < 0.001). When performing trans-vitreal biopsies, ocular oncologists with previous vitreoretinal surgery fellowship training were more likely to use wide-field surgical viewing systems, compared with indirect ophthalmoscopy (82.6% vs. 20.6%, p < 0.001). Surgical complications were rare and occurred more frequently with trans-vitreal biopsies (3.6% vs. 0.46%, p = 0.046). Conclusions: In this multi-center analysis of UM tumor biopsy, surgical yield was high for obtaining tumor tissue for GEP and cytopathology analysis with both trans-scleral and trans-vitreal techniques. Fellowship-trained ocular oncologists’ preferred intraocular biopsy techniques associated strongly with tumor location, tumor thickness, and fellowship training of the surgeon. Short-term complication rates were low.
AB - Purpose: To investigate the relationship between surgical approach for intraocular tumor biopsy of uveal melanoma and tumor morphologic features such as size and intraocular location and the effect of these variables on diagnostic yield and biopsy outcome. Methods: Consecutive patients from nine Ocular Oncology centers with uveal melanoma (UM) undergoing tumor biopsy immediately preceding I125 plaque brachytherapy with tissue sent for gene expression profiling (GEP) testing were reviewed retrospectively. Results: Three hundred sixty patients were included (50% men, mean age 60.2 years). Overall biopsy yield was 99% and 83% for GEP and cytopathology, respectively. Surgeon choice of biopsy approach (trans-vitreal vs. trans-scleral) was found to associate with both tumor location and tumor thickness. A trans-scleral rather than trans-vitreal approach was used more commonly for anteriorly located tumors (92% vs. 38% of posterior tumors, p < 0.001) and thicker tumors (86% vs. 55% of thin tumors, p < 0.001). When performing trans-vitreal biopsies, ocular oncologists with previous vitreoretinal surgery fellowship training were more likely to use wide-field surgical viewing systems, compared with indirect ophthalmoscopy (82.6% vs. 20.6%, p < 0.001). Surgical complications were rare and occurred more frequently with trans-vitreal biopsies (3.6% vs. 0.46%, p = 0.046). Conclusions: In this multi-center analysis of UM tumor biopsy, surgical yield was high for obtaining tumor tissue for GEP and cytopathology analysis with both trans-scleral and trans-vitreal techniques. Fellowship-trained ocular oncologists’ preferred intraocular biopsy techniques associated strongly with tumor location, tumor thickness, and fellowship training of the surgeon. Short-term complication rates were low.
KW - Oncology
KW - Ophthalmology
UR - http://www.scopus.com/inward/record.url?scp=85076043539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076043539&partnerID=8YFLogxK
U2 - 10.1007/s00417-019-04531-8
DO - 10.1007/s00417-019-04531-8
M3 - Article
C2 - 31807898
AN - SCOPUS:85076043539
VL - 258
SP - 427
EP - 435
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
SN - 0721-832X
IS - 2
ER -